• Home
  • News
2024.11.19 | views:142
디엑스앤브이엑스, 사업개발·글로벌 딜 전문가 윤명진 전무 영입
2024.11.18 | views:105
디엑스앤브이엑스 "'MEDICA 2024'서 유럽시장 판로 모색"
2024.11.18 | views:16
디엑스앤브이엑스 "'MEDICA 2024'서 유럽시장 판로 모색"
2024.11.01 | views:246
디엑스앤브이엑스, mRNA 백신 한계 극복 기술 개발
2024.11.01 | views:271
DXVX Develops Groundbreaking Technology to Overcome mRNA Vaccine Storage Limitations Verifies Possibility of Room-Temperature Storage for Over 10 Years Through Preliminary Research
2024.11.01 | views:139
DX&VX Selected for Korea's First ARPA-H Project in 2024, Focusing on Room Temperature and Extra-Long-Term Vaccine Storage Technology
2024.10.30 | views:175
Dx&Vx, ‘상온 초장기 비축 mRNA백신소재 및 대량생산 공정기술 개발’ 국책과제 선정
2024.10.30 | views:219
Dx&Vx, 'Room temperature ultra-long-term stockpiling mRNA vaccine material and mass production process technology development' selected as national projec
2024.10.30 | views:56
DXVX, ‘상온 초장기 비축 mRNA 백신 소재 및 대량 생산 공정 기술 개발’ 국책과제 선정
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8.   
  • 10F, 173, Digital-ro, Geumcheon-gu, Seoul (Gasan-dong, Elysian)
  • Tel : 02-890-8700
  • IR Service : 02-6964-8770
  • Fax : 02-6964-8755

About Us

Goals & Promise

Leadership

Company History

IR

Notice & IR

Disclosure Information

Dx&Vx 2023 Award Impact

Contact

Private Policy Terms of Use twitter icon @dxvx_official
© 2024 Dx&Vx. All Rights Reserved.